Park J B, Schiffrin E L
MRC Multidisciplinary Research Group on Hypertension, Clinical Research Institute of Montréal, 110 Pine Avenue West, Montréal, Québec, Canada H2W 1R7.
Curr Hypertens Rep. 2000 Jun;2(3):280-8. doi: 10.1007/s11906-000-0011-5.
Hypertension is associated with alterations in the structure, function, and mechanical properties of large and small arteries. Changes in the endothelium, smooth muscle cell, extracellular matrix, and possibly the adventitia, contribute to complications of hypertension. In large arteries, vascular hypertrophy is found, often with increased stiffness of media components. In small arteries, particularly in mild hypertension, rearrangement of smooth muscle cells around a smaller lumen without changes in media volume (eutrophic remodeling) occurs; in more severe hypertension, hypertrophic remodeling with increased vascular stiffness can be found. Vascular remodeling is accompanied by an increase in the extracellular matrix, particularly collagen deposition. Recent studies have demonstrated that vascular remodeling and endothelial dysfunction of small and large vessels may be normalized by treatment with some antihypertensive agents (angiotensin converting enzyme inhibitors, angiotensin AT(1) receptor antagonists, and long-acting calcium channel blockers). Angiotensin converting enzyme inhibitors have now been shown to improve outcomes in hypertensive patients, an effect that may in part be related to the vascular protective effects reviewed here.
高血压与大、小动脉的结构、功能及力学特性改变相关。内皮细胞、平滑肌细胞、细胞外基质以及可能的外膜发生变化,会导致高血压并发症。在大动脉中,可发现血管肥大,常伴有中膜成分硬度增加。在小动脉中,尤其是在轻度高血压时,平滑肌细胞围绕较小管腔重排,而中膜体积无变化(营养性重塑);在更严重的高血压中,可发现伴有血管硬度增加的肥厚性重塑。血管重塑伴随着细胞外基质增加,尤其是胶原蛋白沉积。最近的研究表明,使用某些抗高血压药物(血管紧张素转换酶抑制剂、血管紧张素AT(1)受体拮抗剂和长效钙通道阻滞剂)治疗可使小血管和大血管的血管重塑及内皮功能障碍恢复正常。现已证明血管紧张素转换酶抑制剂可改善高血压患者的预后,这一作用可能部分与此处所述的血管保护作用有关。